Dr. Arturo Taca

Dr. Arturo C. Taca, MD
Medical Director
As a psychiatrist and addictionologist, Dr. Arturo Taca has long been at
the forefront of developing innovative solutions for persons struggling
with mental health issues such as addiction and treatment-resistant
depression.
Dr. Taca graduated from The University of the East Medical School in
Manila, Philippines and completed his psychiatric residency training at St.
Louis University School of Medicine, where he was the Chief Resident of
the Department of Psychiatry. He is adjunct faculty at St. Louis University
and continues to teach and supervise residents and medical students. Dr. Taca is also involved in the
newly formed Addiction Medicine Fellowship at St. Louis University through the Department of
Family Medicine.
Dr. Taca is triple board-certified and is a Diplomate in Psychiatry, Addiction Medicine, and
Preventative Medicine. Additionally, Dr. Taca is a distinguished Fellow of the American Society of
Addiction Medicine (ASAM), where he served as the president of ASAM - Midwest Chapter. Before his
presidency, he was elected to the Executive Board of American Society of Addiction Medicine (ASAM)
as alternate Regional Director for Region VII which covers the 7 states of AR, OK, KS, LA, MO, NE, and
TX.
Currently, Dr. Taca is the Medical Director of INSynergy Treatment Center in St. Louis, Missouri. He
founded INSynergy in response to a dire need to provide effective, evidence-based, and cost-
effective treatment solutions for motivated persons struggling with addictions. Dr. Taca and his
team at INSynergy were instrumental in developing a unique protocol using a percutaneous nerve
stimulator, the NSS-2 Bridge, to reduce symptoms of opioid withdrawal. FDA cleared, the NSS-2
Bridge was the first device of its kind for the specific use of helping reduce symptoms of opioid
withdrawal.
Dr. Taca first introduced TMS services to the St. Louis area in 2014, though interest in the field of
neurostimulation began in the early 2000s when he was involved in the Vagus Nerve Stimulation
(VNS) trials at St. Louis University School of Medicine. TMS is currently approved for Major
Depression and OCD and is being studied in opioid addiction, bipolar depression, and other
psychiatric conditions. Cranial nerve stimulators such as the NSS-2 Bridge, Drug Relief, and S.T.

Genesis are FDA cleared to be used in opioid withdrawal and chronic pain. Vagus nerve stimulators
have been approved for the treatment of Major Depression and Epilepsy. Dr. Taca believes that
these new neurostimulation treatments will play a major role in difficult-to-treat neuropsychiatric
conditions.
In addition to his board certifications, Dr. Taca was voted one of the “Best Doctors of America in
Psychiatry and Addiction Psychiatry” by his peers. Only 5% of all doctors in the U.S. are recognized
with this distinction and are selected by a consensus of more than one million votes cast by doctors
across the country. He has been a “Best Doc” since 2009.
At Speranza Therapeutics, Dr. Taca oversees all the clinical operations and will join the executive
leadership in continuing to research and develop innovative products and services. He will also lead
efforts in clinical strategy and work with Board of Directors and Advisors on prescribing guidelines
and best practices.